[144] CORCEPT THERAPEUTICS INC SEC Filing
Corcept Therapeutics Inc. insider plans another share sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Corcept Therapeutics Inc. insider plans another share sale. A Form 144 notice discloses an intended sale of up to 20,000 shares of Corcept common stock through Stifel Nicolaus & Company Inc. on or about 01/06/2026, with an indicated aggregate market value of $699,000.00. The filing notes that 105,190,000 Corcept common shares were outstanding, providing context for the size of the planned transaction.
The 20,000 shares to be sold were acquired on 01/06/2026 via a stock option exercise from Corcept Therapeutics Inc., paid in cash. Over the prior three months, the same seller, William Guyer, reported three separate sales of 20,000 Corcept common shares each (on 10/07/2025, 11/05/2025, and 12/02/2025) with gross proceeds of $1,798,781.00, $1,507,121.00, and $1,601,525.00, respectively.
AI-generated analysis. How Rhea-AI works. Not financial advice.